Publish in this journal
Journal Information
Vol. 15. Issue 2.
Pages 61-62 (March - April 2019)
Vol. 15. Issue 2.
Pages 61-62 (March - April 2019)
Editorial
DOI: 10.1016/j.reumae.2018.12.010
Full text access
Experience of Biological Therapy Units in Rheumatoid Arthritis and Other Autoimmune Diseases
Experiencia de unidades de terapias biológicas en artritis reumatoide y otras enfermedades autoinmunes
Visits
...
Pedro Santos-Moreno
Corresponding author
pedrosantosmoreno@hotmail.com

Corresponding author.
, Omaira Valencia
Biomab – Centro de Artritis Reumatoide, Bogotá, Colombia
Article information
Full Text
Bibliography
Download PDF
Statistics
Full Text

As a centre for the comprehensive treatment of rheumatoid arthritis (RA) and as professionals who work in everyday practice to achieve better clinical results in patients treated with biological therapies, we were interested in reviewing the paper recently published in the Reumatología Clínica journal by Álvaro-Gracia et al. on the follow-up and monitoring of the use of biological agents in different medical specialities and diseases, in a biological therapy unit (BTU) in a university hospital.

The existence of a BTU is not only associated with the application of biological medication; in our experience, the BTU improves patient adherence to follow-up and treatment, and it is associated with better education and clinical control, above all in patients with a low socio-economic level and/or those who lack a good family and/or social support network; it also leads to better control and the early identification of adverse events.

This is why we are interested in the paper by Álvaro-Gracia et al., most particularly in the results of RA. We found that the differences between survival rates of the therapies in the different diseases made complete sense, and in particular the survival rate in RA (38.4 months). This is the disease for which biological therapies are prescribed the most often, and it has been proven that the reasons for interruption were lack of efficacy, loss of effectiveness and adverse reactions.1

The survival time of drugs in this report differs from the analysis of data by the CORRONA registry, where the average time at which therapies were changed or interrupted was 25.1 months for patients with RA. The most common reason for interruption was loss of efficacy, followed by questions of safety, the preference of the doctor, the preference of the patient and access to the treatment.2

In a 36-month follow-up of patients treated with 3 alternative anti-TNF in a cohort of 307 subjects with RA that was undertaken in our BTU, it was found that 97% completed the follow-up at 24 months and that 95% did so at 36 months; with an adverse events rate (AER) of 20% per year that differed between different medications; the lowest AER was for etanercept, at 12%, and the highest was for infliximab, at 24%.3 The paper by Álvaro-Gracia et al., shows a very similar result for the same agent (12%), while the biological agent used in rheumatology with the higher AER include anakinra (28.6%), followed by rituximab (24.6%) and infliximab (24%).1

The similarities between the results of both follow-up studies is consistent with previous studies, showing that even when agents belong to the same pharmaceutical group, as is the case with infliximab and etanercept, they may differ in terms of response efficacy and the percentage of adverse effects, as was previously described in several follow-up studies of patients under treatment with biological therapies.4–9

It should be pointed out that in analyses of this type of medication survival rates, the latter are also associated with external variables such as the type of coverage, specialist and patient preferences and limited access to biological therapies, as described in the CORRONA analysis2; our recommendation for studies of this type is therefore that data should be analysed according to disease and type of medication, and that when possible they should take into account variables connected with coverage, specialist and patient preferences, combinations of biological therapies with methotrexate and barriers against access, most especially to offer more information about the reasons for treatment discontinuation.

Financing

Pedro Santos-Moreno and Omaira Valencia declare that they received no financing for the preparation of this document.

Conflict of Interests

Pedro Santos-Moreno declares that he has received fees for congresses, advisory boards, research and other items from Abbvie, Abbott, Janssen, Pfizer, UCB, Biopas, Pharmetique, La Sante, Lafrancol, Bristol, Roche, Sanofi, Lilly and Novartis.

Omaira Valencia has no conflict of interests to declare.

References
[1]
J.M. Álvaro-Gracia, M. Arredondo, E. Daudén, V. Meca-Lallana, A. Morell, J.P. Gisbert, et al.
Launch and preliminary analysis of La Princesa's Inter-specialists Biological Therapies Unit.
Reumatol Clin, (2019),
[in press]
[2]
V. Strand, P. Miller, S.A. Williams, K. Saunders, S. Grant, J. Kremer.
Discontinuation of biologic therapy in rheumatoid arthritis: analysis from the Corrona RA Registry.
Rheumatol Ther, 4 (2017), pp. 489-502
Available from: http://www.medengine.com/Redeem/ [accessed 15.10.18]
[3]
P. Santos-Moreno, G. Sánchez, D. Gómez, J. Bello-Gualtero, C. Castro.
Direct comparative effectiveness among 3 anti-tumor necrosis factor biologics in a real-life cohort of patients with rheumatoid arthritis.
J Clin Rheumatol, 22 (2016), pp. 57-62
[4]
K.T. Park, A. Sin, M. Wu, D. Bass, J. Bhattacharya.
Utilization trends of anti-TNF agents and health outcomes in adults and children with inflammatory bowel diseases.
Inflamm Bowel Dis [Internet], 20 (2014 July), pp. 1242-1249
Available from: http://www.ncbi.nlm.nih.gov/pubmed/24846718 [accessed 15.10.18]
[5]
G. Quintana, J.P. Restrepo, H. Cáceres, J. Rueda, D. Rosselli.
Economic evaluation of the treatment of rheumatoid arthritis with anti-TNF biological therapy in Colombia.
Acta Médica Colomb [Internet], 36 (2011), pp. 24-29
Available from: http://www.scielo.org.co/pdf/amc/v36n1/v36n1a05.pdf [accessed 15.10.18]
[6]
J.S. Smolen, R. Landewé, F.C. Breedveld, M. Buch, G. Burmester, M. Dougados, et al.
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update.
Ann Rheum Dis, 73 (2014), pp. 492-509
[7]
R.A. Burke, N.D. White.
Biologic disease-modifying antirheumatic drugs.
PSAP [Internet], (2014),
[8]
S. Ajeganova, H.W. van Steenbergen, J.A.B. van Nies, L.E. Burgers, T.W.J. Huizinga, A.H.M. van der Helm-van Mil.
Disease-modifying antirheumatic drug-free sustained remission in rheumatoid arthritis: An increasingly achievable outcome with subsidence of disease symptoms.
Ann Rheum Dis, 75 (2016), pp. 867-873
[9]
J.A. Singh, A. Hossain, E. Tanjong Ghogomu, A.S. Mudano, L.J. Maxwell, R. Buchbinder, et al.
Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.
Cochrane Database Syst Rev [Internet], 3 (2017), pp. CD012591
Available from: http://www.ncbi.nlm.nih.gov/pubmed/28282491 [accessed 19.4.18]

Please cite this article as: Santos-Moreno P, Valencia O. Experiencia de unidades de terapias biológicas en artritis reumatoide y otras enfermedades autoinmunes. Reumatol Clín. 2019;15:61–62.

Copyright © 2019. Elsevier España, S.L.U. and Sociedad Española de Reumatología y Colegio Mexicano de Reumatología
Idiomas
Reumatología Clínica (English Edition)

Subscribe to our newsletter

Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.